A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (NCT05907304)
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 12 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- University of California, San Francisco — San Francisco, California
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- Florida Cancer Specialists - St. Petersburg — St. Petersburg, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Henry Ford Health System — Detroit, Michigan
- Washington University School of Medicine — St Louis, Missouri
- Comprehensive Cancer Center of Nevada (CCCN) — Las Vegas, Nevada
- Oregon Health & Science University — Portland, Oregon
- SCRI Oncology Partners (formerly Tennessee Oncology) — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Inova Schar Cancer Institute — Fairfax, Virginia
- NEXT Virginia — Fairfax, Virginia
- University of Wisconsin — Madison, Wisconsin
- Macquarie University — Macquarie Park, New South Wales
- St. Vincent's Hospital — Melbourne, Victoria
- Linear Clinical Research, LTD — Perth,
- Cross Cancer Institute- Alberta Health Services (AHS) — Edmonton, Alberta
- British Columbia Cancer Agency — Vancouver, British Columbia
- London Regional Cancer Center — London, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Inje University Haeundae Paik Hospital — Busan, Busan Gwang'yeogsi
- Samsung Medical Center — Seoul, Seoul Teugbyeolsi
- National Cancer Center — Goyang-si,
- Seoul National University Hospital Bundang — Gyeonggi-do,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Solid Tumors
- A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) — Sioux Falls, South Dakota
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — Boston, Massachusetts
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Birmingham, Alabama
- A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Los Angeles, California
Explore by condition: All Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.